Sarcoidosis Clinical Trial
Official title:
Use of CXCL9 as a Biomarker of Acthar Efficacy
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
The investigators will test whether Acthar gel's anti-inflammatory properties will modulate immune cells and lead to decreases in blood biomarkers and improvements in clinical parameters. Specific Aim 1 will examine the levels of the predictive biomarker, chemokine ligand 9 (CXCL9), and related transcripts, and determine whether they decrease in participants over time while taking Acthar. Specific Aim 2 will test whether the biologic changes measured in blood correlate to clinical markers, including lung function and symptom scores. Since the investigators have found that CXCL9 predicts clinical course, they hypothesize that CXCL9 transcript levels in the blood will decrease over time in pulmonary sarcoidosis participants whose clinical outcome measures improve with Acthar. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04008069 -
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
|
Phase 2 | |
| Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
| Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
| Completed |
NCT00373555 -
Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis
|
N/A | |
| Completed |
NCT00326534 -
Rickettsial Genesis to Sarcoidosis in Denmark
|
N/A | |
| Completed |
NCT00274352 -
A Study of Adalimumab to Treat Sarcoidosis of the Skin
|
Phase 2 | |
| Recruiting |
NCT00470327 -
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
|
||
| Completed |
NCT00512967 -
The Occurence of Inflammation and Oxidative Stress in Lung Diseases
|
N/A | |
| Recruiting |
NCT01745237 -
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
|
||
| Completed |
NCT00369980 -
Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient
|
N/A | |
| Completed |
NCT00379275 -
Eye and Immunogenetic Features of Sarcoidosis
|
N/A | |
| Completed |
NCT00366509 -
Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
|
||
| Completed |
NCT06396910 -
TB and Sarcoidosis Granuloma
|
||
| Completed |
NCT04156789 -
Obstructive Sleep Apnoea in Sarcoidosis
|
||
| Recruiting |
NCT02916459 -
EBUS-TBNA vs Flex 19G EBUS-TBNA
|
N/A | |
| Recruiting |
NCT02827734 -
Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
|
||
| Completed |
NCT02546388 -
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
|
N/A | |
| Completed |
NCT01687517 -
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
|
Phase 3 | |
| Completed |
NCT01139710 -
Sarcoidosis-associated Pulmonary Hypertension
|
N/A | |
| Terminated |
NCT00747461 -
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
|
Phase 4 |